Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A

Nature Biotechnology

Volumn 17, Issue 6, 1999, Pages 583-587

  Mizuta, Tadashi ^a,c   Fujiwara, Masatoshi ^a,c   Hatta, Toshifumi ^b   Abe, Takayuki ^b   Miyano Kurosaki, Naoko ^b   Shigeta, Shiro ^c   Yokota, Tomoyuki ^a,c   Takaku, Hiroshi ^b  

^a Rational Drug Design Laboratories   (Japan)

^b CHIBA INSTITUTE OF TECHNOLOGY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Animal model; Antisense therapeutics; Influenza A virus

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; RNA POLYMERASE; VIRUS RNA;

ARTICLE; CODON; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; INFLUENZA VIRUS A; LUNG PARENCHYMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRANSLATION INITIATION; VIROGENESIS; VIRUS GENE;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CODON, INITIATOR; DNA PRIMERS; DNA-DIRECTED RNA POLYMERASES; INFLUENZA A VIRUS; LUNG; MICE; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SIZE; ORTHOMYXOVIRIDAE INFECTIONS; RIBAVIRIN; SURVIVAL RATE; THIONUCLEOTIDES;

EID: 0033014533     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/9893     Document Type: Article

References (46)

1. Detjen, B.M., St. Angelo, C. Katze, M.G. & Krug, R.M. The three influenza virus polymerase (P) proteins not associated with viral nucleocapsids in the infected cell are in the form of a complex. J. Virol. 61, 16-22 (1987).
2. Nakagawa, Y. The RNA polymerase PB2 subunits is not required for replication of the influenza virus genome but is involved in capped mRNA synthesis. J. Virol. 69, 728-733 (1995).
3. Sanz-Ezquerro, J.J., de la Luna, S., Ortin, J. & Nieto, A. Individual expression of influenza virus PA protein induces degradation of coexpressed proteins. J. Virol. 69, 2420-2426 (1995).
4. Rothenberg, M. et al. Oligodeoxynucleotides as antisense inhibitor of gene expression: therapeutic implications. J. Natl. Cancer. Inst. 81, 1538-1544 (1989).
5. Zamecnik, P.C. & Stephenson, M.L. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-284 (1978).
6. Zamecnik, P.C., Goodchild, J., Taguchi, Y. & Sarin, P.S. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic immunodeficiency oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. USA 83, 4143-4148 (1986).
7. Miller, P.S. et al. Control ribonucleic acid function by oligonucleotide methylphosphonates. Biochimie 67, 769-776 (1985).
8. Smith, C.C., Aurelian, L, Reddy, M.P., Miller, P.S. & Ts'o, P.O.P. Antiviral effect of an oligo (nuclaoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc. Natl. Acad. Sci. USA 83, 2787-2791 (1986).
9. Matsukura, M. et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84, 7706-7710 (1987).
10. Zerial, A., Thuong, N.T. & Hélène, C. Selective inhibition of the cytopathic effect of type A influenza virus by oligonucleotides covalently linked to an intercalating agent. Nucleic Acids Res. 15, 9909-9919 (1987).
11. Leiter, J.M.E., Agrawal, S., Palese, P. & Zamecnik, P.C. Inhibition of influenza virus replication by phosphorothioate oligonucleotides. Proc. Natl. Acad. Sci. USA B7, 3430-3434 (1990).
12. Kim, S-G. et al. Anti-HIV activities and physicochemical properties of phosphorothioate analogues complementary to HIV sequences. Bioorg. Med. Chem. Lett. 3, 1223-1228 (1993).
13. Kim, S-G. et al. Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Bioorg. Med. Chem. Lett. 3, 49-54 (1995).
14. Whitesell, L., Rosolen, A. & Neckers, L.M. In vitro modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. Antisense Res. Dev. 1, 343-350 (1991).
15. Simons, M., Edelman, E.R., DeKeyser, J-L., Langer, R. & Rosenberg, R.D. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70 (1992).
16. Skorski, T. et al. Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 91, 4504-4508 (1994).
17. Hélène, C. & Toulmé, J.J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta 149, 99-125 (1990).
18. Erickson, R.P. & Yzant, J.G. Gene regulation, biology of antisense RNA and DNA (Raven, London; 1992).
19. Miller, P.S., Mc Parland, K.B., Yayaraman, N. & Ts'o, P.O.P. Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20, 1874-1880 (1981).
20. Stec, W., Zon, G., Egan, W. & Stec, B. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides. J. Am. Chem. Soc 106, 6077-6079 (1984).
21. Agrawal, S. et al. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85, 7079-7083 (1988).
22. Wickstroms, E.L. et al. Human promyelocitic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide target against c-myc mRNA. Proc. Natl. Acad. Sci. USA 85, 1028-1032 (1988).
23. Stein, C.A. et al. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J. Acq. Imm. Defi. Synd. 4, 686-6939 (1991).
24. Yakubov, L.A. et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86, 6454-6458 (1989).
25. Leonetti, J.P., Machy, P., Degols, G., Lebleu, B. & Leserman, L Antibody targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibited viral replication. Proc. Natl. Acad. Sci. USA 87, 2448-2451 (1989).
26. Milhaud, P.G., Machy, P., Colote, S., Lebleu, B. & Leserman, L. Free and liposome-encapsulated double-stranded RNAs as inducers of Interferon, interleukin-6, and cellular toxicily. J. Interferon Res. 11, 261-265 (1991).
27. Thierry, A.R. & Dritschilo, A. Intracellular availability unmodified phosphorothioate and liposomally encapsulated oligodeoxyribonucleotides for antisense activity. Nucleic Acids Res. 21, 5691-5698 (1992).
28. Hatta, T. et al. Inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by unmodified, phospnorothioated, and liposomally encapsulated oligonucleotides. Biochem. Biophys. Res. Commun. 223, 341-346 (1996).
29. Hatta, T., Takai, K., Nakada, S., Yokota, T. & Takaku, H. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Biochem. Biophys. Res. Commun. 232, 545-549 (1997).
30. Bennett, C.F., Chaing, M-Y., Chang, H., Schoemaker, J.E. & Mirabelli, C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033 (1992).
31. Stewart, M.J. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum. Gene Ther. 3, 267-275 (1992).
32. Keogh, M.-C. High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid-DNA complex. Gene Ther. 4, 162-171 (1997).
33. Lewis, J.G. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA 93, 3176-3181 (1996).
34. Abe, T. et al. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells. Antivir. Chem. Chemother. 9, 253-262 (1998).
35. Yamashita, M., Krystal, M. & Palese, P. Comparison of the three large polymerase proteins of influenza A, B, and C viruses. Virology 171, 458-466 (1989).
36. Jambrina, E., Barcena, J., Uez, O. & Portela, A. The three subunits of the polymerase and the nucleoprotein of influenza B virus are the minimum set of viral proteins required for expression of a model RNA template. Virology 235, 209-217 (1997).
37. Agatsuma, T. et al. Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288. Antiviral Res. 34, 121-130 (1997).
38. Stein, C.A. Does antisense exist?: it may, but only under very special circumstances. Nat. Med. 11, 1119-1121 (1995).
39. Stein, C.A. & Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261, 1004-1012 (1993).
40. Stein, C.A. &Krieg, A.M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4, 67-69 (1994).
41. Wagner, R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-335 (1994).
42. Davis, H.L et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-676 (1998).
43. Brazolot Millan, C.L., Weeratna, R., Krieg, A.M., Siegrist, C-A. & Davis, H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95, 15553-15558 (1998).
44. Liu, Y. et al. Cationic liposome-mediated intravenous gene delivery. J. Biol. Chem. 270, 24864-24870 (1995).
45. Zhu, N., Liggitt, D., Liu, Y. & Debs, R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 261, 209-211 (1993).
46. Tsan, M.-F., Tsan, G.L. & White, J.E. Surfactant inhibits cationic liposome-mediated gene transfer. Hum. Gene Ther. 8, 817-825 (1997).